6月12日，科伦博泰生物盘中上涨7.35%，报423.4港元，成交额1.8亿港元。消息面上，公司当日公告，已收到宜联生物医药就YL201对外授权应分享给公司的收入人民币6.025亿元，截至公告日已累计收到和解款项合计人民币7.027亿元，大额现金回流显著改善公司资金面。
此外，公司核心产品芦康沙妥珠单抗III期OptiTROP-Lung05研究数据近期持续催化，合作伙伴Windward Bio主导的SKB378/WIN378针对COPD的二期临床亦已完成首批患者给药，管线多线推进叠加资金面利好共同提振股价。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.